Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy
Therapeutic Advances in Endocrinology and Metabolism · 2025-11 · 16
DOI: 10.1177/20420188251406554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 17.12.2025. Verfasst von Ola M Al-Sanabra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Balqa Applied University, Al-Salt, Jordan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: β-Thalassemia major patients are frequently vulnerable to endocrine dysfunction due to iron overload from chronic transfusions. This impairs growth, thyroid function, glucose metabolism, and bone health, ultimately compromising quality of life and long-term outcomes.
Objectives
This study investigates the prevalence and pattern of endocrine dysfunction in β-thalassemia major patients receiving iron-chelation therapy and explores associations with iron overload markers.
Methods
This case-control study involved 60 β-thalassemia major patients and 20 age- and sex-matched controls. Hormonal and biochemical parameters were measured and linked to iron status.
Results
Among β-thalassemia major patients (7–35 years), 73.3% ( n = 44/60) were splenectomized; 36 received deferiprone, 19 deferasirox, and 5 deferoxamine. Concerning iron status, both splenectomized and non-splenectomized patients had significantly higher iron and ferritin and lower haptoglobin levels compared to controls. No significant differences were found in hepcidin or hemopexin levels. Regarding thyroid function, about 15% ( n = 9/60) of β-thalassemia major patients had subclinical primary hypothyroidism. Ferritin negatively correlated with free thyroxine ( r = −0.330, p = 0.010). As for glycemic status, 51.7% ( n = 31/60) of β-thalassemia patients had glycated hemoglobin (HbA1c) ⩾6.5% and 38.3% ( n = 23/60) showed impaired fasting blood sugar. With respect to metabolic markers, splenectomized patients had higher fibroblast growth factor 21 (FGF21) than the control ( p = 0.042), while no significant group differences were found in galectin-1 or sortilin. Ferritin correlated significantly and positively with FGF21 levels ( r = 0.353, p = 0.006). With respect to calcium–parathyroid–vitamin D axis, hypoparathyroidism and hyperparathyroidism were each found in 11.7% ( n = 7/60) of β-thalassemia patients. Vitamin D levels were significantly lower in the β-thalassemia groups compared to controls ( p = 0.0001) with 71.7% ( n = 43/60) deficient despite 43.3% ( n = 26/60) receiving supplements. Non-splenectomized patients had higher Procollagen Type I C-Peptide, a bone formation marker, compared to controls.
Conclusion
Endocrine disturbances are common in β-thalassemia major despite chelation therapy. Incorporating endocrine assessment into routine practice is essential for early detection and management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Balqa Applied University, Al-Salt, Jordan.
- Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan.
- Pharmacological and Diagnostic Research Centre, Al-Ahliyya Amman University, Amman 19328, Jordan.
- Arkan Laboratory, Zarqa, Jordan.
- Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Zhejiang, China.
ORCID-Profile: Ola M Al-Sanabra, Manal A Abbas
Zitieren
APA
Al-Sanabra, O. M., Abbas, M. A., Hazàa, A. A., & Hazà, W. J. (2025). Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy. Therapeutic Advances in Endocrinology and Metabolism, 16. https://doi.org/10.1177/20420188251406554
Vancouver
Al-Sanabra OM, Abbas MA, Hazàa AA, Hazà WJ. Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy. Therapeutic Advances in Endocrinology and Metabolism. 2025;16. doi:10.1177/20420188251406554
BibTeX
@article{AlSanabra2025,
author = {Al-Sanabra, Ola M and Abbas, Manal A and Hazàa, Abeer A and Hazà, Wafà J},
title = {Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy},
journal = {Therapeutic Advances in Endocrinology and Metabolism},
year = {2025},
volume = {16},
doi = {10.1177/20420188251406554}
}
EUVIMED